Research Brief — RB-032

The Cost of Complexity: Findings from the 2026 Site Challenges Survey

Published November 2026 — WCG's 2026 Clinical Research Site Challenges Report, released November 4, finds 41% of sites naming trial complexity as their leading operational problem, workloads rising faster than staffing, and AI clauses appearing in contracts well ahead of AI adoption.

Executive Summary

Complexity Is Now the Top Site Problem

WCG's annual survey of clinical research sites is one of the most closely watched measures of site health. The 2026 edition, titled The Cost of Complexity and released on November 4, 2026, is based on responses from more than 400 clinical research professionals.

This year's results show trial complexity overtaking other concerns, a widening gap between workload and staffing, and continued friction in contracts, budgets, and amendments. This brief summarizes the published figures.

Key Findings

41%
Name Complexity the Leading Problem

41% of sites named trial complexity as their leading operational problem, up from 35% in 2025. Two-thirds (66%) rated protocol complexity a high source of overall trial complexity, up from 59%.

40% vs 26%
More Trials, Not More Staff

40% of sites took on moderately more trials this year, while only 26% increased staffing to match.

87%
Report Delays from Amendments

87% of clinical research professionals reported timeline delays caused by amendments. Protocol design changes were a driver of amendments at 78% of sites.

16% vs 44%
AI Adoption vs AI Contract Clauses

Only 16% of sites have implemented AI or automation, yet roughly 44% are already seeing AI-related clauses in their clinical trial agreements.

Behind the Headline Numbers

The report describes a site sector that is busy and strained at once.

1

Workload and Burnout

Two-thirds of sites described their teams as overloaded or at risk of burnout, and fewer than a third said current workloads are sustainable. Site staffing was cited as a top challenge by 38% of sites, up from the previous year.

2

Contracts and Budgets

Contract and budget delays were cited by 37% of sites, also up year over year. Budget negotiation was identified as the single largest source of start-up delay, with most sites placing the full start-up window at two to four months.

3

Financial Effects

Nearly two-thirds of sites said current challenges have hurt their financial performance. Complexity that is not reflected in budgets shows up as unpaid work.

4

AI Arrives in the Contract First

The gap between the 16% of sites using AI and the 44% seeing AI clauses means many sites are being asked to agree to terms about technology they have not yet adopted. Sites should read these clauses closely and understand what they commit to.

Implications for Sites and Sponsors

The survey points to where relief would matter most.

Price Complexity Into Budgets

Sites should itemize the work that complex protocols and amendments create and include it in budgets. Sponsors that recognize this cost will find sites more willing to take on demanding studies.

Match Workload to Capacity

Accepting more trials without more staff is the pattern behind the burnout figures. Capacity planning before accepting a study protects both staff and data quality.

Review AI Terms Early

AI clauses deserve the same legal attention as indemnification or data ownership. Networks can review them once and give all member sites a consistent position.

Conclusions

The 2026 survey shows complexity moving to the top of the list of site problems, with knock-on effects on staffing, timelines, and finances. The findings are consistent with other research this year on protocol burden and start-up delay.

The figures summarized here are drawn from WCG's announcement and press coverage of the report. The full report should be consulted for methodology and question wording.

Sources

This brief summarizes published industry research. Figures are reported as stated in the sources below and have not been independently verified by Clinitiative.

Discuss These Findings with Our Team

Talk with us about what this research means for your protocol, site selection, or enrollment plan.